catapano cv...

Catapano CV – Publications

1: Civenni G, Albino D, Shinde D, Vázquez R, Merulla J, Kokanovic A, Mapelli SN,

Carbone GM, Catapano CV. Transcriptional Reprogramming and Novel Therapeutic

Approaches for Targeting Prostate Cancer Stem Cells. Front Oncol. 2019 May

9;9:385. doi: 10.3389/fonc.2019.00385. eCollection 2019. Review. PubMed PMID:

31143708; PubMed Central PMCID: PMC6521702.

2: Civenni G, Bosotti R, Timpanaro A, Vàzquez R, Merulla J, Pandit S, Rossi S,

Albino D, Allegrini S, Mitra A, Mapelli SN, Vierling L, Giurdanella M, Marchetti

M, Paganoni A, Rinaldi A, Losa M, Mira-Catò E, D'Antuono R, Morone D, Rezai K,

D'Ambrosio G, Ouafik L, Mackenzie S, Riveiro ME, Cvitkovic E, Carbone GM,

Catapano CV. Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of

Stem-like Tumor Cells in Human Prostate Cancer. Cell Metab. 2019 May 20. pii:

S1550-4131(19)30244-X. doi: 10.1016/j.cmet.2019.05.004. [Epub ahead of print]

PubMed PMID: 31130467.

3: Scimeca M, Urbano N, Bonfiglio R, Mapelli SN, Catapano CV, Carbone GM, Ciuffa

S, Tavolozza M, Schillaci O, Mauriello A, Bonanno E. Prostate Osteoblast-Like

Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer

Patients. Contrast Media Mol Imaging. 2018 Dec 9;2018:9840962. doi:

10.1155/2018/9840962. eCollection 2018. Erratum in: Contrast Media Mol Imaging.

2019 Mar 11;2019:7843735. PubMed PMID: 30627063; PubMed Central PMCID:

PMC6305022.

4: Mapelli SN, Napoli S, Pisignano G, Garcia-Escudero R, Carbone GM, Catapano CV.

Deciphering the complexity of human noncoding promoter-proximal transcriptome.

Bioinformatics. 2018 Dec 10. doi: 10.1093/bioinformatics/bty981. [Epub ahead of

print] PubMed PMID: 30535182.

5: Civenni G, Carbone GM, Catapano CV. Overview of Genetically Engineered Mouse

Models of Prostate Cancer and Their Applications in Drug Discovery. Curr Protoc

Pharmacol. 2018 Jun;81(1):e39. doi: 10.1002/cpph.39. Epub 2018 Jun 7. Review.


6: Sgrignani J, Garofalo M, Matkovic M, Merulla J, Catapano CV, Cavalli A.

Structural Biology of STAT3 and Its Implications for Anticancer Therapies

Development. Int J Mol Sci. 2018 May 28;19(6). pii: E1591. doi:

10.3390/ijms19061591. Review. PubMed PMID: 29843450; PubMed Central PMCID:

PMC6032208.

7: Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E,

Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A,

D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M,

Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J,

Carracedo A, Alimonti A. Compartmentalized activities of the pyruvate

dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet. 2018

Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. Erratum in:

Nat Genet. 2018 Sep;50(9):1343. PubMed PMID: 29335542; PubMed Central PMCID:

PMC5810912.

8: Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A,

Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L,

Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus

RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA,

Wild PJ, Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on

BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017

Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14. PubMed PMID:


9: Napoli S, Piccinelli V, Mapelli SN, Pisignano G, Catapano CV. Natural

antisense transcripts drive a regulatory cascade controlling c-MYC transcription.

RNA Biol. 2017 Dec 2;14(12):1742-1755. doi: 10.1080/15476286.2017.1356564. Epub

2017 Oct 11. PubMed PMID: 28805496; PubMed Central PMCID: PMC5731802.

10: Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono

R, Perez L, Levy DE, Pricl S, Carbone GM, Catapano CV. Mitochondrial dysfunction

induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic

lethality in cancer cells. Proc Natl Acad Sci U S A. 2017 Jun

20;114(25):E4924-E4933. doi: 10.1073/pnas.1615730114. Epub 2017 Jun 5. PubMed

PMID: 28584133; PubMed Central PMCID: PMC5488915.

11: Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Di Marco S, Civenni

G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, Mello-Grand M,

Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV. A

promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin

silencing in human cancers. Nat Commun. 2017 May 30;8:15622. doi:

10.1038/ncomms15622. PubMed PMID: 28555645; PubMed Central PMCID: PMC5459991.

12: Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M,

Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo

P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the

oral smoothened inhibitor sonidegib in combination with paclitaxel in patients

with advanced solid tumors. Invest New Drugs. 2017 Dec;35(6):766-772. doi:

10.1007/s10637-017-0454-z. Epub 2017 Mar 20. PubMed PMID: 28317088.

13: Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi

S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A,

Chiorino G, Catapano CV, Carbone GM. MicroRNA-424 impairs ubiquitination to

activate STAT3 and promote prostate tumor progression. J Clin Invest. 2016 Dec

1;126(12):4585-4602. doi: 10.1172/JCI86505. Epub 2016 Nov 7. PubMed PMID:


14: Rabi T, Catapano CV. Aphanin, a triterpenoid from Amoora rohituka inhibits

K-Ras mutant activity and STAT3 in pancreatic carcinoma cells. Tumour Biol. 2016

Sep;37(9):12455-12464. Epub 2016 Jun 22. PubMed PMID: 27333990.

15: Roos M, Pradère U, Ngondo RP, Behera A, Allegrini S, Civenni G, Zagalak JA,

Marchand JR, Menzi M, Towbin H, Scheuermann J, Neri D, Caflisch A, Catapano CV,

Ciaudo C, Hall J. A Small-Molecule Inhibitor of Lin28. ACS Chem Biol. 2016 Oct

21;11(10):2773-2781. Epub 2016 Aug 22. PubMed PMID: 27548809.

16: Albino D, Civenni G, Rossi S, Mitra A, Catapano CV, Carbone GM. The ETS

factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the

prostate cancer stem-like compartment. Oncotarget. 2016 Nov 22;7(47):76756-76768.

doi: 10.18632/oncotarget.12525. PubMed PMID: 27732936; PubMed Central PMCID:

PMC5363547.

17: Albino D, Civenni G, Dallavalle C, Roos M, Jahns H, Curti L, Rossi S, Pinton

S, D'Ambrosio G, Sessa F, Hall J, Catapano CV, Carbone GM. Activation of the

Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like

Phenotype in Prostate Cancer. Cancer Res. 2016 Jun 15;76(12):3629-43. doi:

10.1158/0008-5472.CAN-15-2665. Epub 2016 May 2. PubMed PMID: 27197175.

18: Civenni G, Longoni N, Costales P, Dallavalle C, García Inclán C, Albino D,

Nuñez LE, Morís F, Carbone GM, Catapano CV. EC-70124, a Novel Glycosylated

Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell

Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB. Mol Cancer Ther.

2016 May;15(5):806-18. doi: 10.1158/1535-7163.MCT-15-0791. Epub 2016 Jan 29.


19: Sgrignani J, Olsson S, Ekonomiuk D, Genini D, Krause R, Catapano CV, Cavalli

A. Molecular Determinants for Unphosphorylated STAT3 Dimerization Determined by

Integrative Modeling. Biochemistry. 2015 Sep 8;54(35):5489-501. doi:

10.1021/bi501529x. Epub 2015 Aug 25. PubMed PMID: 26283080.

20: Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati

A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R,

Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L,

Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A. A chemogenomic

screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient

tumours. Nat Commun. 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227. PubMed PMID:

26085373.

21: Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M,

Montani E, Rinaldi A, Montemurro F, Catapano C, Bertoni F, Alimonti A.

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes

trastuzumab resistance in breast cancer. Cell Rep. 2015 Apr 28;11(4):564-76. doi:

10.1016/j.celrep.2015.03.044. Epub 2015 Apr 16. PubMed PMID: 25892239.

22: Brambilla L, Genini D, Laurini E, Merulla J, Perez L, Fermeglia M, Carbone

GM, Pricl S, Catapano CV. Hitting the right spot: Mechanism of action of

OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of

Transcription 3 (STAT3). Mol Oncol. 2015 Jun;9(6):1194-206. doi:

10.1016/j.molonc.2015.02.012. Epub 2015 Mar 5. PubMed PMID: 25777967; PubMed

Central PMCID: PMC5528765.

23: Roos M, Rebhan MA, Lucic M, Pavlicek D, Pradere U, Towbin H, Civenni G,

Catapano CV, Hall J. Short loop-targeting oligoribonucleotides antagonize Lin28

and enable pre-let-7 processing and suppression of cell growth in let-7-deficient

cancer cells. Nucleic Acids Res. 2015 Jan;43(2):e9. doi: 10.1093/nar/gku1090.

Epub 2014 Nov 6. PubMed PMID: 25378324; PubMed Central PMCID: PMC4333367.

24: Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S,

Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero

R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A. Enhancing

chemotherapy efficacy in Pten-deficient prostate tumors by activating the

senescence-associated antitumor immunity. Cell Rep. 2014 Oct 9;9(1):75-89. doi:

10.1016/j.celrep.2014.08.044. Epub 2014 Sep 25. PubMed PMID: 25263564.

25: Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, D'Antuono R, Montani

E, Garcia-Escudero R, Guccini I, Da Silva-Alvarez S, Collado M, Eisenberger M,

Zhang Z, Catapano C, Grassi F, Alimonti A. Tumour-infiltrating Gr-1+ myeloid

cells antagonize senescence in cancer. Nature. 2014 Nov 6;515(7525):134-7. doi:

10.1038/nature13638. Epub 2014 Aug 24. PubMed PMID: 25156255.

26: Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, Pinton

S, Sarti M, Carbone GM, Catapano CV. RNAi-mediated silencing of Myc transcription

inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer

Res. 2013 Nov 15;73(22):6816-27. doi: 10.1158/0008-5472.CAN-13-0615. Epub 2013

Sep 24. PubMed PMID: 24063893.

27: Liu X, Liu C, Catapano CV, Peng L, Zhou J, Rocchi P. Structurally flexible

triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to

deliver RNAi-based therapeutics. Biotechnol Adv. 2014 Jul-Aug;32(4):844-52. doi:

10.1016/j.biotechadv.2013.08.001. Epub 2013 Aug 9. Review. PubMed PMID: 23938269.

28: Sarti M, Pinton S, Limoni C, Carbone GM, Pagani O, Cavalli F, Catapano CV.

Differential expression of testin and survivin in breast cancer subtypes. Oncol

Rep. 2013 Aug;30(2):824-32. doi: 10.3892/or.2013.2502. Epub 2013 May 28. PubMed

PMID: 23715752.

29: Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S,

Mello-Grand M, Ostano P, D'Ambrosio G, Sessa F, Garcia-Escudero R, Thalmann GN,

Chiorino G, Catapano CV, Carbone GM. ETS transcription factor ESE1/ELF3

orchestrates a positive feedback loop that constitutively activates NF-κB and

drives prostate cancer progression. Cancer Res. 2013 Jul 15;73(14):4533-47. doi:

10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16. PubMed PMID: 23687337.

30: Malek A, Gyorffy B, Catapano CV, Schäfer R. Selection of optimal combinations

of target genes for therapeutic multi-gene silencing based on miRNA

co-regulation. Cancer Gene Ther. 2013 May;20(5):326-9. doi: 10.1038/cgt.2013.20.

Epub 2013 Apr 26. PubMed PMID: 23618947.

31: Genini D, Garcia-Escudero R, Carbone GM, Catapano CV. Transcriptional and

Non-Transcriptional Functions of PPARβ/δ in Non-Small Cell Lung Cancer. PLoS One.

2012;7(9):e46009. doi: 10.1371/journal.pone.0046009. Epub 2012 Sep 25. PubMed

PMID: 23049921; PubMed Central PMCID: PMC3457940.

32: Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S,

D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM. Aberrant

expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes

and is associated with prostate cancer progression. Oncogene. 2013 May

2;32(18):2315-24, 2324.e1-4. doi: 10.1038/onc.2012.245. Epub 2012 Jun 25. PubMed

PMID: 22733135.

33: Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D,

Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H,

Colombo N. An open-label phase 2 study of twice-weekly bortezomib and

intermittent pegylated liposomal doxorubicin in patients with ovarian cancer

failing platinum-containing regimens. Int J Gynecol Cancer. 2012

Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a. PubMed PMID: 22635029.

34: Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F,

Catapano CV. Modulation of the activity of Sp transcription factors by

mithramycin analogues as a new strategy for treatment of metastatic prostate

cancer. PLoS One. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. Epub 2012

Apr 19. PubMed PMID: 22545098; PubMed Central PMCID: PMC3334962.

35: Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G, Thalmann G,

D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM. ESE3/EHF

controls epithelial cell differentiation and its loss leads to prostate tumors

with mesenchymal and stem-like features. Cancer Res. 2012 Jun 1;72(11):2889-900.

doi: 10.1158/0008-5472.CAN-12-0212. Epub 2012 Apr 13. PubMed PMID: 22505649.

36: Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet

P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G,

Catapano CV, Carbone GM, Bonapace IM. The SRA protein UHRF1 promotes epigenetic

crosstalks and is involved in prostate cancer progression. Oncogene. 2012 Nov

15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13. PubMed PMID:

22330138.

37: Pandey R, Mehrotra D, Catapano C, Choubey V, Sarin R, Mahdi AA, Singh S.

Association of mitochondrial deoxyribonucleic acid mutation with polymorphism in

CYP2E1 gene in oral carcinogenesis. J Oral Biol Craniofac Res. 2012

Jan-Apr;2(1):4-9. doi: 10.1016/S2212-4268(12)60003-7. PubMed PMID: 25756024;

PubMed Central PMCID: PMC3941659.

38: Capobianco ML, Catapano CV. Daunomycin-TFO Conjugates for Downregulation of

Gene Expression. Top Curr Chem. 2008;283:45-71. doi: 10.1007/128_2007_2. PubMed

PMID: 23605628.

39: Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano

CV, Carbone GM. Reduced expression and tumor suppressor function of the ETS

transcription factor ESE-3 in prostate cancer. Oncogene. 2008 May

1;27(20):2877-85. Epub 2007 Nov 26. PubMed PMID: 18037958.

40: Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F.

Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human

mantle cell lymphoma. Leuk Lymphoma. 2007 Feb;48(2):410-2. PubMed PMID: 17325905.

41: Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, Catapano

CV, Bertoni F. Cyclin-dependent kinase inhibitor seliciclib shows in vitro

activity in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007 Jan;48(1):158-67.


42: Genini D, Catapano CV. Block of nuclear receptor ubiquitination. A mechanism

of ligand-dependent control of peroxisome proliferator-activated receptor delta

activity. J Biol Chem. 2007 Apr 20;282(16):11776-85. Epub 2007 Feb 26. PubMed

PMID: 17324937.

43: Genini D, Catapano CV. Control of peroxisome proliferator-activated receptor

fate by the ubiquitinproteasome system. J Recept Signal Transduct Res.

2006;26(5-6):679-92. Review. PubMed PMID: 17118805.

44: Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C,

Bertoni F, Carbone GM, Catapano CV. Cellular and molecular consequences of

peroxisome proliferator-activated receptor-gamma activation in ovarian cancer

cells. Neoplasia. 2006 Oct;8(10):851-61. PubMed PMID: 17032502; PubMed Central

PMCID: PMC1715924.

45: Pucci D, Albertini V, Bloise R, Bellusci A, Cataldi A, Catapano CV, Ghedini

M, Crispini A. Synthesis and anticancer activity of cyclopalladated complexes

containing 4-hydroxy-acridine. J Inorg Biochem. 2006 Sep;100(9):1575-8. Epub 2006

May 5. PubMed PMID: 16828871.

46: Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, Rossi D, Zucca

E, Ponzoni M, Catapano C, Tibiletti MG, Paulli M, Gaidano G, Bertoni F.

Comparative genome-wide profiling of post-transplant lymphoproliferative

disorders and diffuse large B-cell lymphomas. Br J Haematol. 2006

Jul;134(1):27-36. PubMed PMID: 16803564.

47: Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M,

Bergant J, Bertoni F, Carbone GM, Rohr J, Catapano CV. Novel GC-rich DNA-binding

compound produced by a genetically engineered mutant of the mithramycin producer

Streptomyces argillaceus exhibits improved transcriptional repressor activity:

implications for cancer therapy. Nucleic Acids Res. 2006 Mar 29;34(6):1721-34.

Print 2006. PubMed PMID: 16571899; PubMed Central PMCID: PMC1420802.

48: Napoli S, Negri U, Arcamone F, Capobianco ML, Carbone GM, Catapano CV. Growth

inhibition and apoptosis induced by daunomycin-conjugated triplex-forming

oligonucleotides targeting the c-myc gene in prostate cancer cells. Nucleic Acids

Res. 2006 Jan 30;34(2):734-44. Print 2006. PubMed PMID: 16449206; PubMed Central

PMCID: PMC1356532.

49: Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G,

Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E,

Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F. Genomic and

expression profiling identifies the B-cell associated tyrosine kinase Syk as a

possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006

Feb;132(3):303-16. PubMed PMID: 16409295.

50: Napoli S, Carbone GM, Catapano CV, Shaw N, Arya DP. Neomycin improves

cationic lipid-mediated transfection of DNA in human cells. Bioorg Med Chem Lett.

2005 Jul 15;15(14):3467-9. PubMed PMID: 15950473.

51: Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E,

Catapano C, Cavalli F, Gianella-Borradori A, Maccallum DE, Bertoni F. In vitro

activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine)

in mantle cell lymphomas. Ann Oncol. 2005 Jul;16(7):1169-76. Epub 2005 Apr 25.


52: Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. Triplex

DNA-mediated downregulation of Ets2 expression results in growth inhibition and

apoptosis in human prostate cancer cells. Nucleic Acids Res. 2004 Aug

16;32(14):4358-67. Print 2004. PubMed PMID: 15314206; PubMed Central PMCID:

PMC514370.

53: Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C,

Freeman KD, Green MR. A phase I study of sequential administration of escalating

doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in

patients with solid tumors. Cancer. 2004 Jun 15;100(12):2671-9. PubMed PMID:

15197811.

54: Carbone GM, McGuffie E, Napoli S, Flanagan CE, Dembech C, Negri U, Arcamone

F, Capobianco ML, Catapano CV. DNA binding and antigene activity of a

daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter

of the human c-myc gene. Nucleic Acids Res. 2004 Apr 30;32(8):2396-410. Print

2004. PubMed PMID: 15121897; PubMed Central PMCID: PMC419437.

55: Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, Rohr J.

Inhibition of c-src transcription by mithramycin: structure-activity

relationships of biosynthetically produced mithramycin analogues using the c-src

promoter as target. Biochemistry. 2003 Jul 15;42(27):8313-24. PubMed PMID:

12846580.

56: Carbone GM, McGuffie EM, Collier A, Catapano CV. Selective inhibition of

transcription of the Ets2 gene in prostate cancer cells by a triplex-forming

oligonucleotide. Nucleic Acids Res. 2003 Feb 1;31(3):833-43. PubMed PMID:


57: McGuffie EM, Catapano CV. Design of a novel triple helix-forming

oligodeoxyribonucleotide directed to the major promoter of the c-myc gene.

Nucleic Acids Res. 2002 Jun 15;30(12):2701-9. PubMed PMID: 12060688; PubMed

Central PMCID: PMC117288.

58: Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan

and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001

Sep;48(3):188-96. PubMed PMID: 11592339.

59: Carbone GM, Catapano CV, Fernandes DJ. Imbalanced DNA synthesis induced by

cytosine arabinoside and fludarabine in human leukemia cells. Biochem Pharmacol.

2001 Jul 1;62(1):101-10. PubMed PMID: 11377401.

60: McGuffie EM, Pacheco D, Carbone GM, Catapano CV. Antigene and

antiproliferative effects of a c-myc-targeting phosphorothioate triple

helix-forming oligonucleotide in human leukemia cells. Cancer Res. 2000 Jul

15;60(14):3790-9. PubMed PMID: 10919652.

61: Catapano CV, McGuffie EM, Pacheco D, Carbone GM. Inhibition of gene

expression and cell proliferation by triple helix-forming oligonucleotides

directed to the c-myc gene. Biochemistry. 2000 May 2;39(17):5126-38. PubMed PMID:

10819980.

62: Erba E, Bergamaschi D, Ronzoni S, Faretta M, Taverna S, Bonfanti M, Catapano

CV, Faircloth G, Jimeno J, D'Incalci M. Mode of action of thiocoraline, a natural

marine compound with anti-tumour activity. Br J Cancer. 1999 Jun;80(7):971-80.

PubMed PMID: 10362104; PubMed Central PMCID: PMC2363046.

63: Catapano CV, Carbone GM, Pisani F, Qiu J, Fernandes DJ. Arrest of replication

fork progression at sites of topoisomerase II-mediated DNA cleavage in human

leukemia CEM cells incubated with VM-26. Biochemistry. 1997 May

13;36(19):5739-48. PubMed PMID: 9153414.

64: Qiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase II alpha

complexes with nascent DNA is related to VM-26-induced cytotoxicity.

Biochemistry. 1996 Dec 17;35(50):16354-60. PubMed PMID: 8973211.

65: Catapano CV, Carbone GM, Fernandes DJ. The nuclear matrix as a target for

cancer therapy. Ann Oncol. 1996 Sep;7(7):659-66. Review. PubMed PMID: 8905022.

66: Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF,

Sartorelli AC. Increased rate of adenosine triphosphate-dependent etoposide

(VP-16) efflux in a murine leukemia cell line overexpressing the multidrug

resistance-associated protein (MRP) gene. Cancer Res. 1995 Oct 1;55(19):4352-60.


67: Catapano CV, Dayton JS, Mitchell BS, Fernandes DJ. GTP depletion induced by

IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol. 1995

May;47(5):948-55. PubMed PMID: 7746281.

68: Fernandes DJ, Catapano CV. The nuclear matrix as a site of anticancer drug

action. Int Rev Cytol. 1995;162A:539-76. Review. PubMed PMID: 8575887.

69: Fernandes DJ, Qiu J, Catapano CV. DNA topoisomerase II isozymes involved in

anticancer drug action and resistance. Adv Enzyme Regul. 1995;35:265-81. PubMed

PMID: 7572348.

70: Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. Subcellular

distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by

VM-26. Biochem Pharmacol. 1994 Nov 1;48(9):1785-95. PubMed PMID: 7980648.

71: Limonta M, Colombo T, Damia G, Catapano CV, Conter V, Gervasoni M, Masera G,

Liso V, Specchia G, Giudici G, et al. Cytotoxic activity and mechanism of action

of 5-Aza-2'-deoxycytidine in human CML cells. Leuk Res. 1993 Nov;17(11):977-82.


72: Catapano CV, Perrino FW, Fernandes DJ. Primer RNA chain termination induced

by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. A mechanism of DNA

synthesis inhibition. J Biol Chem. 1993 Apr 5;268(10):7179-85. PubMed PMID:

7681821.

73: Taverna P, Catapano CV, Citti L, Bonfanti M, D'Incalci M. Influence of

O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse

leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs.

1992 Aug;3(4):401-5. PubMed PMID: 1421437.

74: Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in

CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res. 1991 Apr

1;51(7):1829-35. PubMed PMID: 1706219.

75: Fernandes DJ, Catapano CV. Nuclear matrix targets for anticancer agents.

Cancer Cells. 1991 Apr;3(4):134-40. Review. PubMed PMID: 1652999.

76: D'Incalci M, Taverna P, Erba E, Filippeschi S, Potenza D, Mariani L, Citti L,

Catapano CV. O6-methylguanine and temozolomide can reverse the resistance to

chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res. 1991

Jan-Feb;11(1):115-21. PubMed PMID: 2018345.

77: Limonta M, Ubezio P, Catapano CV, Conter V, Costato C, Masera G, Specchia G,

Liso V, Barbui T, Giudici G, et al. Doxorubicin and m-AMSA induced DNA damage in

blast cells from AML patients. Leuk Res. 1991;15(1):19-24. PubMed PMID: 1997742.

78: Limonta M, Biondi A, Giudici G, Specchia G, Catapano C, Masera G, Barbui T,

D'Incalci M. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and

its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia

cells. Cancer Chemother Pharmacol. 1990;26(5):340-2. PubMed PMID: 2208574.

79: Zucchetti M, Catapano CV, Filippeschi S, Erba E, D'Incalci M. Temozolomide

induced differentiation of K562 leukemia cells is not mediated by gene

hypomethylation. Biochem Pharmacol. 1989 Jul 1;38(13):2069-75. PubMed PMID:

2660797.

80: Citti L, Mariani L, Catapano CV, Malvaldi G. The relevance of DNA repair in

the cytotoxic response of mammalian cells to alkylating agents. Ann Ist Super

Sanita. 1989;25(1):5-9. PubMed PMID: 2751197.

81: Catapano CV, Guaitani A, Broggini M, Corada M, Bartosek I, Italia C, Donelli

MG. Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as

compared to daunorubicin in rats. Anticancer Res. 1988 Jul-Aug;8(4):725-31.


82: Catapano CV, Ubezio P, Rossi V, Conter V, Jancovich M, D'Incalci M.

Intracellular drug concentration and DNA damage in human childhood leukemic cells

exposed to doxorubicin. Biochem Pharmacol. 1988 May 1;37(9):1863-4. PubMed PMID:

3377855.

83: Donelli MG, Dolfini E, Catapano C, Finazzi M, Mandelli GC, Volontè M, Fuhrman

Conti AM. Studies on the biology, histology and cytogenetics of two sublines of a

murine ovarian reticular cell sarcoma : Biology of M5 and R16 murine tumor.

Cytotechnology. 1987 Oct;1(1):87-90. doi: 10.1007/BF00351130. PubMed PMID:

22358448.

84: Catapano CV, Broggini M, Erba E, Ponti M, Mariani L, Citti L, D'Incalci M. In

vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia

sensitive and resistant to chloroethylnitrosoureas. Cancer Res. 1987 Sep

15;47(18):4884-9. PubMed PMID: 3621181.

catapano cv...

Documents